AR045893A1 - Particulas para liberar en forma sostenida un medicamento y un metodo para preparar tales particulas - Google Patents
Particulas para liberar en forma sostenida un medicamento y un metodo para preparar tales particulasInfo
- Publication number
- AR045893A1 AR045893A1 ARP040102231A ARP040102231A AR045893A1 AR 045893 A1 AR045893 A1 AR 045893A1 AR P040102231 A ARP040102231 A AR P040102231A AR P040102231 A ARP040102231 A AR P040102231A AR 045893 A1 AR045893 A1 AR 045893A1
- Authority
- AR
- Argentina
- Prior art keywords
- particles
- release
- sustained
- theophylline
- base material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Partículas de liberación sostenida de teofilina que contienen éster de ácido graso de poliglicerol como un material de base de la matriz, que tiene una estructura de partículas del núcleo homogéneo, que puede enmascarar efectivamente el sabor desagradable de los medicamentos, y que presenta estabilidad al almacenamiento. Método para preparar partículas de liberación sostenida de teofilina que comprende los pasos de calentar un material de base de la matriz que contiene éster de ácido graso de poliglicerol, teofilina y etil celulosa par dar una mezcla fundida; enfriar por rociado la mezcla fundida para obtener partículas del núcleo esféricas que tienen un diámetro de partículas promedio de 250 micrones o menos; y aplicar partículas finas a la partículas del núcleo por recubrimiento por fusión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003184040 | 2003-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045893A1 true AR045893A1 (es) | 2005-11-16 |
Family
ID=33549598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102231A AR045893A1 (es) | 2003-06-27 | 2004-06-25 | Particulas para liberar en forma sostenida un medicamento y un metodo para preparar tales particulas |
Country Status (14)
Country | Link |
---|---|
US (1) | US8734843B2 (es) |
EP (1) | EP1640006A4 (es) |
JP (1) | JP4592590B2 (es) |
KR (1) | KR101096357B1 (es) |
CN (2) | CN1812793A (es) |
AR (1) | AR045893A1 (es) |
AU (1) | AU2004251541B2 (es) |
BR (1) | BRPI0411882A (es) |
CA (1) | CA2529475C (es) |
HK (1) | HK1118484A1 (es) |
MX (1) | MXPA05014194A (es) |
MY (1) | MY145784A (es) |
TW (1) | TW200505485A (es) |
WO (1) | WO2005000312A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146553A1 (en) * | 2002-12-23 | 2004-07-29 | Aventis Pharma S.A. | Compositions for oral administration of active principles requiring masking of taste |
JPWO2006059716A1 (ja) * | 2004-12-03 | 2008-06-05 | 武田薬品工業株式会社 | 固形製剤 |
JP5252926B2 (ja) * | 2005-12-22 | 2013-07-31 | 大塚製薬株式会社 | 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤 |
ZA200805793B (en) * | 2005-12-22 | 2009-11-25 | Otsuka Pharma Co Ltd | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol |
CA2681802C (en) * | 2007-02-16 | 2015-12-08 | Elevance Renewable Sciences, Inc. | Wax compositions and methods of preparing wax compositions |
US8163301B2 (en) | 2007-03-22 | 2012-04-24 | Magceutics, Inc. | Magnesium compositions and uses thereof for metabolic disorders |
US8377473B2 (en) * | 2009-07-01 | 2013-02-19 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
EP2540318B1 (en) | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
JP5870023B2 (ja) * | 2010-02-22 | 2016-02-24 | 第一三共株式会社 | 経口用徐放性固形製剤 |
KR102127625B1 (ko) | 2012-09-03 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물 |
CN107050023A (zh) * | 2017-01-13 | 2017-08-18 | 北京顺慈医药科技有限公司 | 一种盐酸小檗碱的制剂及遮盖药物不良味道的制剂方法 |
CN112020351A (zh) | 2017-12-28 | 2020-12-01 | 大日本住友制药株式会社 | 新型微粒包衣(含有药物的中空颗粒及其制法) |
CN111566130B (zh) | 2018-01-05 | 2023-01-24 | 凸版印刷株式会社 | 复合颗粒、复合颗粒的制造方法、干燥粉体以及成型用树脂组合物 |
WO2019208801A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 徐放性複合粒子、徐放性複合粒子の製造方法、乾燥粉体及び壁紙 |
CN108904451A (zh) * | 2018-07-27 | 2018-11-30 | 广州柏赛罗药业有限公司 | 缓释制剂 |
JP6618595B1 (ja) * | 2018-10-16 | 2019-12-11 | 佐藤薬品工業株式会社 | カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法 |
WO2020083412A1 (de) * | 2018-10-22 | 2020-04-30 | Ioi Oleo Gmbh | Additiv für ein zur verpressung zu formkörpern vorgesehenes pulver |
CN114209887B (zh) * | 2021-08-24 | 2023-03-03 | 杭州协合医疗用品有限公司 | 一种含可控降解聚酯微球的注射用凝胶 |
CN113877000B (zh) * | 2021-10-13 | 2023-01-24 | 科笛生物医药(无锡)有限公司 | 注射用微球组合物及其应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264131A (en) * | 1964-05-11 | 1966-08-02 | Polymer Corp | Process for fusion coating and materials used therein |
JPH0647531B2 (ja) * | 1986-02-06 | 1994-06-22 | 第一製薬株式会社 | 徐放性粒状物の製造法 |
JP2893191B2 (ja) | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
JPH03124063A (ja) * | 1989-10-06 | 1991-05-27 | Ricoh Co Ltd | イメージセンサ |
JP3078859B2 (ja) | 1990-02-23 | 2000-08-21 | 武田薬品工業株式会社 | 安定な放出制御性製剤用コーティング剤 |
IE65045B1 (en) * | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
JP3130058B2 (ja) | 1991-02-15 | 2001-01-31 | 第一製薬株式会社 | マスクされた粒状物 |
JP2915590B2 (ja) | 1991-02-15 | 1999-07-05 | 第一製薬株式会社 | マスクされた粒状物 |
US5359170A (en) | 1992-02-18 | 1994-10-25 | At&T Global Information Solutions Company | Apparatus for bonding external leads of an integrated circuit |
JP2949448B2 (ja) | 1992-11-30 | 1999-09-13 | ケーヴィ ファーマセチカル カンパニー | 味を隠された医薬材料 |
JPH07112940A (ja) * | 1993-08-26 | 1995-05-02 | Takeda Chem Ind Ltd | 徐放性非経口投与製剤およびその製造方法 |
EA000467B1 (ru) | 1995-07-21 | 1999-08-26 | Дайити Фармасьютикал Ко., Лтд. | Гранулированный препарат и способ его получения |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
JP3611456B2 (ja) | 1997-09-30 | 2005-01-19 | 日研化学株式会社 | テオフィリン徐放性錠剤 |
JP3372242B2 (ja) | 1999-08-04 | 2003-01-27 | 沢井製薬株式会社 | 徐放性微粒子製剤及びその製造方法 |
JP2001055342A (ja) * | 1999-08-17 | 2001-02-27 | Sakamoto Yakuhin Kogyo Co Ltd | 錠剤、錠菓用滑沢剤 |
JP2003508430A (ja) * | 1999-08-31 | 2003-03-04 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | トラマドールサッカリナートを含有する徐放性投薬形 |
US6537671B2 (en) * | 2000-12-05 | 2003-03-25 | Alpha Coating Technologies, Llc | Coating powders having enhanced electrostatic chargeability |
JP2002179571A (ja) | 2000-12-11 | 2002-06-26 | Nikken Chem Co Ltd | 小型徐放性錠剤 |
JP2002226304A (ja) | 2001-01-31 | 2002-08-14 | Mitsui Chemicals Inc | 徐放型微粒子の製造方法 |
JP4310605B2 (ja) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
AU2003211243B8 (en) * | 2002-02-21 | 2008-11-06 | Otsuka Pharmaceutical Co., Ltd. | Sustained release preparations and process for producing the same |
-
2004
- 2004-06-17 AU AU2004251541A patent/AU2004251541B2/en not_active Ceased
- 2004-06-17 CA CA2529475A patent/CA2529475C/en not_active Expired - Fee Related
- 2004-06-17 JP JP2005511026A patent/JP4592590B2/ja not_active Expired - Fee Related
- 2004-06-17 WO PCT/JP2004/008824 patent/WO2005000312A1/ja active Application Filing
- 2004-06-17 CN CNA2004800181177A patent/CN1812793A/zh active Pending
- 2004-06-17 MX MXPA05014194A patent/MXPA05014194A/es active IP Right Grant
- 2004-06-17 KR KR1020057025130A patent/KR101096357B1/ko not_active IP Right Cessation
- 2004-06-17 US US10/561,444 patent/US8734843B2/en not_active Expired - Fee Related
- 2004-06-17 CN CN2008100067985A patent/CN101219115B/zh not_active Expired - Fee Related
- 2004-06-17 BR BRPI0411882-0A patent/BRPI0411882A/pt not_active Application Discontinuation
- 2004-06-17 EP EP04746293A patent/EP1640006A4/en not_active Withdrawn
- 2004-06-23 TW TW093118070A patent/TW200505485A/zh not_active IP Right Cessation
- 2004-06-24 MY MYPI20042492A patent/MY145784A/en unknown
- 2004-06-25 AR ARP040102231A patent/AR045893A1/es unknown
-
2008
- 2008-11-13 HK HK08112467.1A patent/HK1118484A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101219115A (zh) | 2008-07-16 |
MY145784A (en) | 2012-04-30 |
EP1640006A1 (en) | 2006-03-29 |
HK1118484A1 (en) | 2009-02-13 |
JP4592590B2 (ja) | 2010-12-01 |
JPWO2005000312A1 (ja) | 2006-08-03 |
AU2004251541B2 (en) | 2010-03-04 |
CA2529475C (en) | 2012-08-07 |
US8734843B2 (en) | 2014-05-27 |
EP1640006A4 (en) | 2012-04-04 |
TW200505485A (en) | 2005-02-16 |
MXPA05014194A (es) | 2006-02-24 |
KR20060026071A (ko) | 2006-03-22 |
AU2004251541A1 (en) | 2005-01-06 |
CA2529475A1 (en) | 2005-01-06 |
KR101096357B1 (ko) | 2011-12-20 |
CN1812793A (zh) | 2006-08-02 |
WO2005000312A8 (ja) | 2005-02-24 |
TWI333858B (es) | 2010-12-01 |
WO2005000312A1 (ja) | 2005-01-06 |
CN101219115B (zh) | 2012-09-19 |
BRPI0411882A (pt) | 2006-08-29 |
US20070098843A1 (en) | 2007-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045893A1 (es) | Particulas para liberar en forma sostenida un medicamento y un metodo para preparar tales particulas | |
Rodriguez et al. | Description and preliminary evaluation of a new ultrasonic atomizer for spray-congealing processes | |
DE69509671D1 (de) | Pharmazeutische zusammensetzung mit einem schmelzbaren traegermaterial und verfahren zu seiner herstellung | |
NZ526015A (en) | Pharmaceutical preparation comprising an active dispersed on a matrix | |
Dey et al. | Formulation and optimization of sustained release stavudine microspheres using response surface methodology | |
KR950703935A (ko) | 맛을 차단하는 약제학적 조성물 | |
JPH09175992A (ja) | カプセル含有錠剤型浴用剤 | |
JP2019532921A (ja) | 固形医薬品投与形態の製造のためのプロセス | |
US20180338927A1 (en) | Ether cellulose derivative microparticle | |
RU2012102772A (ru) | Фармацевтическая таблетка, содержащая заполненную жидкостью капсулу | |
CA2535013A1 (en) | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents | |
JP2010254689A (ja) | リン酸アスコルビルマグネシウム含有凍結乾燥成形品 | |
JP2019529545A (ja) | マイクロスフェアおよびその製造方法 | |
JP6312689B2 (ja) | 植物性シームレスカプセル、及びその利用 | |
KR20180019081A (ko) | 식물성 버터 조성물 | |
JP6576596B1 (ja) | マイクロニードルシート及びその製造方法 | |
CA2798068C (en) | New dosage form for cineole | |
RU2011127248A (ru) | Экструдаты с игловидными действующими веществами | |
JP4940724B2 (ja) | 脂質被覆物の製造方法 | |
Kokina et al. | Essential oil/alginate microcapsules; obtaining and applying | |
El-Laithy et al. | Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks | |
KR102382417B1 (ko) | 성형 마이크로스피큘의 모양을 조절하는 조성물 및 이의 제조 방법 | |
JP5852816B2 (ja) | 液状医薬組成物、及びこれを含有する軟カプセル剤 | |
KR20200070539A (ko) | 유효성분을 함유하는 왁스 파티클 및 이의 제조방법 | |
JP5838104B2 (ja) | 液体含浸固形物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |